Newsroom | 48598 results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award...

NEWARK, Del.--(BUSINESS WIRE)--CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnersh...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has authorized the dose-ranging study REVISE, which will investigate the efficacy and...

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed publication of Phase 2b trial results in The Lancet Microbe (Link). The published research article summarizes the CHAMPION-1 clinical study of BPZE1, a randomized, double-blind, placebo-controlled study conducted in healthy adults in a controlled human infection model. BP...

SCHAUMBURG, Ill. & PARSIPPANY, N.J.--(BUSINESS WIRE)--The Society of Urologic Oncology (SUO) and Ferring Pharmaceuticals today announced the SUO NMIBC (non-muscle invasive bladder cancer) Fellows Research Grant, created to support outstanding clinical research investigators committed to advancing the understanding and treatment of NMIBC. Two applicants will receive the SUO NMIBC Fellows Research Grant, provided by an educational grant from Ferring Pharmaceuticals. “Advancing research in NMIBC i...

BOSTON--(BUSINESS WIRE)--Instem Unveils New Global Headquarters in Boston, MA Reflecting Customer Obsession, Strategic Growth, and a New Era for Instem...

PITTSBURGH--(BUSINESS WIRE)--CytoAgents announced a poster presentation of new CTO1681 clinical data at the 67th American Society of Hematology Annual Meeting....

MADISON, Wis.--(BUSINESS WIRE)--Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies for the treatment of patients with cancer, today announced that it has dosed the first patient in its Phase 1 clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC). ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy was invented and developed by Rein...

NEW YORK--(BUSINESS WIRE)--Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the publication of a new study in the Journal Pharmaceutics (MDPI) that highlights the effectiveness of its proprietary carbidopa/levodopa formulations (LXM.5) for the treatment of Parkinson's disease. The pharmacokinetic study demonstrated that Laxxon’s novel dosage forms significantly improved bioavailability compared to Sin...

SEATTLE--(BUSINESS WIRE)--AGC Biologics is partnering with ATUM to integrate technology designed to increase yields and shorten the path to clinical trials....